- Home
- REF vs OMER Comparison
REF vs OMER Comparison
Compare REF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$15.04
HOLD
Current Price
$18.61
Company Overview
Basic Information| Metric | REF | OMER |
|---|---|---|
| Founded | N/A | 1994 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 958.2M | 844.6M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | REF | OMER |
|---|---|---|
| Price | $15.04 | $18.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 464.7K | ★ 2.3M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $25.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.83 | $3.94 |
| 52 Week High | $17.26 | $19.65 |
Technical Indicators
Market Signals| Indicator | REF | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 72.53 |
| Support Level | $12.83 | $9.12 |
| Resistance Level | $16.74 | N/A |
| Average True Range (ATR) | 0.86 | 0.93 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 60.36 | 87.58 |
Price Performance
Historical Comparison REF
OMER
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.